Piper Sandler has initiated coverage of Agomab Therapeutics (NASDAQ: AGMB) with an above-average rating and a price target of $60.00, compared with the stock’s recent close of $12.82. The firm’s initiation follows a review of Agomab’s pipeline, including Ontunisertib, an oral ALK5 inhibitor being developed for fibrostenotic Crohn’s disease and broader inflammatory bowel disease indications.
The analyst cited Agomab’s progress in aligning its Phase 2b NOV-ERA clinical trial design with the U.S. Food and Drug Administration, which has agreed to endoscopic passability at week 24 as the primary endpoint. The trial, expected to commence in the second half of 2026, has also received approval from the U.S. Institutional Review Board and Health Canada, with clinical trial applications submitted across the European Union and Asia-Pacific regions.
Agomab’s pipeline includes AGMB-447, an inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis, and STENOVA, a Phase 2a open-label extension study. The company’s market capitalization stands at approximately $631 million, with shares down 3.25% at $12.82 in recent trading. Piper Sandler’s valuation implies a potential upside of nearly 370% from current levels.
The initiation follows similar coverage by B.Riley and H.C. Wainwright, both assigning buy ratings with price targets of $34 and $35, respectively. Agomab’s focus on the TGF-β/ALK5 pathway, which avoids heart valve toxicity concerns, has drawn comparisons to peers like Sarepta Therapeutics (valued at $9.5 billion) and Abivax (valued at $10.3 billion), though Agomab’s market cap remains significantly smaller.
InvestingPro’s financial health index for Agomab shows a current ratio of 12.88, described as "Good," reflecting strong liquidity relative to short-term obligations.
